In addition, low SETD2 expression was linked with significantly shorter overall survival in SHH medulloblastoma (Fig. 5g, two-sided log-rank test, p < 0.018, SHH alpha (SHH3) subgroup, which is the molecular subgroup to which most CT medulloblastomas belong). The gene discussed is SETD2; the disease is medulloblastoma.